WuXi Biologics CRO Services

Each month, we share a step from our exclusive infographic designed to help you successfully navigate early-stage therapeutic antibody production. Ready for Step 3? This month, we’re spotlighting our expertise in transfection methods and cell status monitoring. Stay tuned for step four—purification and quality control—coming next month. 🧑🔬Do you find infographics like this one useful? If you do, please give our post a like! #infographic #TherapeuticAntibody #AntibodyProductionb #scientificdiscovery

Will you be attending PEGS Europe (November 5-7) in Barcelona, Spain? Jijie Gu, PhD, CTO at WuXi Biologics, will be speaking during the event on Thursday, November 7 at 12:15 PM CET. Dr. Gu will present "Combining Primary, Secondary, and Tertiary Signals with Immune Cell Engagers to Supercharge Anti-Tumor Immunity.” Our teams will be available to discuss your R&D and drug discovery goals during the event. Contact us and we'll set up a convenient time to discuss your outsourcing needs. Request a Meeting: https://lnkd.in/gvNFGynY #PEGSEurope #Biologics #DrugDiscovery #Immunotherapy #BarcelonaEvents #Pharmaceuticals #LifeSciences #Biotech

✈️ Are you attending Antibody Therapeutics Xchange in Maryland on October 28? Don’t miss an exclusive spotlight presentation by Sundee Dees, Ph.D., Senior Manager of Business Development at WuXi Biologics’ CRO Services, where she will discuss innovative production strategies for Fab, ScFv, and VHH, with tailored engineering approaches for each molecule. Additionally, join our roundtable discussion on “Emerging Opportunities and Challenges in Bi-/Multi-Specific Antibody Drug Development,” led by Dr. Zeck Huang, Senior Director & Nonclinical Lead at WuXi Biologics. Want to connect with us? Schedule a meeting with our Business Development team here: ▶️ https://lnkd.in/eAg4H58n. #AntibodyTherapeutics #DrugDevelopment #DrugDiscovery #AntibodyProduction

WuXi Biologics offers extensive and integrated Preclinical Candidates (PCC) screening studies in the evaluation and selection of lead mAb (or other biologics) therapeutic candidates. Preclinical assessment is just one part of our wide-ranging antibody discovery services. Let's get started. https://lnkd.in/e4sVN6wF #biologics #antibodydisocovery #biotherapeutics #biopharma #drugdevelopment

📰Have you heard about our monthly newsletter, “In the Fold”? Every month, we deliver valuable insights into antibody discovery and R&D protein production right to your inbox. For this month’s issue, we’ll be featuring two papers: ● Researchers developed bispecific antibody mimics that redirect T-cells to cancer cells with potency influenced by Fab linkage and flexible valency, demonstrating tumor reduction in a breast cancer model. Read the paper: ▶️https://lnkd.in/eDc2GwBG ● Researchers introduced an engineered pH-dependent antibody that rapidly reduces levels of allergen-crosslinked IgE and degrades allergens, offering a potential new allergy treatment. Read the paper: ▶️https://lnkd.in/eKXaND_4 Subscribe to stay informed on the latest breakthroughs and gain practical solutions that support your biologics development at every stage. Subscribe Here: ▶️ https://lnkd.in/eH4serWJ #ProteinProduction #DrugDiscovery #AntibodyProduction #WuXiBiologics #Research #BispecificAntibody #Scientificresearch #biotechIndustry

👨🔬Are you looking for efficient solutions for high-titer miniprotein production? Our high-titer, high-throughput CHO expression systems tackle the challenges of traditional E. coli systems, including limited throughput, misfolding and high endotoxin levels. Check out our case study that showcases the HTP production of 76 miniproteins in 3 mL of CHO cells over 2 weeks. The final products achieved a yield of 0.16 mg with 88% purity. Learn More: ▶️ https://lnkd.in/gfZ9Hbd8 #Drugdiscovery #AntibodyDiscovery #WuXiBiologics #CHOCells #AntibodyProduction

Service Spotlight: WuXi Biologics offers extensive lead assessment and optimization services for antibody therapeutics and other biologics. Our team of experts work with you to establish the best path in optimizing your molecule to its target and for its intended purpose. Let's get started. https://lnkd.in/ejJwMXNk #antibodydiscovery #leadoptimization #humanization #biologics #biotherapeutics #biopharma #drugdevelopment #drugdiscovery #biologics

Thank you to everyone who joined us at the Festival of Biologics in Switzerland this year! We enjoyed sharing how our extensive drug discovery and development expertise can provide tailored solutions for every stage of your antibody journey. If you didn’t get a chance to connect with us, feel free to reach out—we’re always ready to discuss your projects and how we can help. Contact us today! ▶️ https://lnkd.in/eAg4H58n #festivalofbiologics #drugdevelopment #antibodydevelopment #bispecificantibody

On-demand Webinar: Bispecific and multispecific antibodies belong to a growing class of biotherapeutics with enormous potential for oncology, neurodegenerative disease, and other applications. Overcoming the technical challenges associated with developing and engineering these complex proteins, compounded by safety and efficacy concerns, is essential for unlocking their full potential. In this GEN webinar, Dr. Jianqing Xu dives into the tools and strategies that overcome these challenges. Watch the webinar on demand: https://lnkd.in/erAApPKh #antibodies #drugdevelopment #bispecificantibody #antibodyengineering #antibodydiscovery #antibodydevelopment

Bispecific antibodies (BsAbs) are at the forefront of therapeutic innovation, but their production is often hindered by challenges such as low titers and difficult-to-remove impurities like homodimers and mispaired species. Additionally, each BsAb format presents unique complexities in the production process. Join our upcoming webinar, “Achieving High Titer and Superior Purity Across Diverse Bispecific Antibody Formats,” on October 30, where we’ll highlight our innovative solutions to these challenges, including ultra-high-titer CHO expression systems, optimized chain ratios, and Intact Mass-assisted purification processes tailored for various formats like CrossMab, WuXiBody, and others. Through detailed case studies, we will demonstrate how these approaches consistently achieve over 98% heterodimer purity and endotoxin levels below 0.1 EU/mg. In this webinar, you will learn: • Innovative strategies to overcome low titers, mispaired species and homodimers. • Advanced chain ratio optimization for formats like CrossMab and WuXiBody, improving expression and titer. • Case studies illustrating Intact Mass-assisted purification tailored for various formats, such as CrossMab, WuXiBody, and ScFv-Fab, consistently achieving heterodimer purity >98% and endotoxin levels <0.1 EU/mg. Register Now: ▶️https://lnkd.in/gcTyUHDD #BispecificAntibodies #DrugDiscovery #Therapeutic #Innovation